Why Do We Want Selective CB2 Medicines?
Some people I have spoken with insist that high THC cannabis does everything that needs to be done; Tetrahydrocannabinol stimulates both the CB1 and CB2 receptors. Those people believe that THC is all we ever need.
Problems related to high doses of THC include anxiety/paranoia, short-term memory loss, impaired coordination, and other incapacitation. These side effects are transient, but can be unpleasant. In the case of the RSO protocol for cancer, the side effects lead many patients to drop the treatment, or reduce the dose greatly. A non-psychoactive medicine that achieves the same results would have obvious advantages. A species of plant other than Canabis sativa would face fewer regulatory issues, and be considered by more people who might benefit from the medicine.
There is also some evidence that stimulating the CB1 receptors can sometimes trigger fibrosis and other undesirable action in the body. 1, 2, 3, 4, 5. By contrast, activation of the CB2 receptors is associated with the prevention of fibrosis. In conditions marked by destructive fibrosis (like Covid-19), it would seem particularly desirable to use a selective CB2 agonist.